These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 32211756

  • 1. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
    Caro L, Nicolau DP, De Waele JJ, Kuti JL, Larson KB, Gadzicki E, Yu B, Zeng Z, Adedoyin A, Rhee EG.
    J Antimicrob Chemother; 2020 Jun 01; 75(6):1546-1553. PubMed ID: 32211756
    [Abstract] [Full Text] [Related]

  • 2. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O.
    J Antimicrob Chemother; 2012 Oct 01; 67(10):2463-9. PubMed ID: 22773741
    [Abstract] [Full Text] [Related]

  • 3. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
    Zhang Z, Patel YT, Fiedler-Kelly J, Feng HP, Bruno CJ, Gao W.
    J Clin Pharmacol; 2021 Feb 01; 61(2):254-268. PubMed ID: 32949031
    [Abstract] [Full Text] [Related]

  • 4. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
    Xiao AJ, Miller BW, Huntington JA, Nicolau DP.
    J Clin Pharmacol; 2016 Jan 01; 56(1):56-66. PubMed ID: 26096377
    [Abstract] [Full Text] [Related]

  • 5. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Gao W, Patel YT, Zhang Z, Johnson MG, Fiedler-Kelly J, Bruno CJ, Rhee EG, Anda C, Feng HP.
    J Clin Pharmacol; 2023 Mar 01; 63(3):352-357. PubMed ID: 36201105
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
    Nicolau DP, De Waele J, Kuti JL, Caro L, Larson KB, Yu B, Gadzicki E, Zeng Z, Rhee EG, Rizk ML.
    Int J Antimicrob Agents; 2021 Apr 01; 57(4):106299. PubMed ID: 33567333
    [Abstract] [Full Text] [Related]

  • 7. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
    Feng HP, Patel YT, Zhang Z, Fiedler-Kelly J, Bruno CJ, Rhee EG, De Anda C, Gao W.
    J Clin Pharmacol; 2023 Feb 01; 63(2):166-171. PubMed ID: 36046982
    [Abstract] [Full Text] [Related]

  • 8. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan 01; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 9. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
    Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, Timsit JF, Wunderink RG, Bruno CJ, Huntington JA, Lin G, Yu B, Butterton JR, Rhee EG.
    Lancet Infect Dis; 2019 Dec 01; 19(12):1299-1311. PubMed ID: 31563344
    [Abstract] [Full Text] [Related]

  • 10. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA.
    Antimicrob Agents Chemother; 2019 Oct 01; 63(10):. PubMed ID: 31358583
    [Abstract] [Full Text] [Related]

  • 11. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
    Gao W, Passarell J, Patel YT, Zhang Z, Lin G, Fiedler-Kelly J, Bruno CJ, Rhee EG, De Anda CS, Feng HP.
    Antimicrob Agents Chemother; 2022 May 17; 66(5):e0139921. PubMed ID: 35471040
    [Abstract] [Full Text] [Related]

  • 12. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
    Katsube T, Nicolau DP, Rodvold KA, Wunderink RG, Echols R, Matsunaga Y, Menon A, Portsmouth S, Wajima T.
    J Antimicrob Chemother; 2021 Oct 11; 76(11):2902-2905. PubMed ID: 34383901
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan.
    Takaya R, Mori N, Saito E, Ohde S.
    BMC Health Serv Res; 2024 Mar 28; 24(1):389. PubMed ID: 38549158
    [Abstract] [Full Text] [Related]

  • 14. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
    Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA.
    Antimicrob Agents Chemother; 2019 Dec 20; 64(1):. PubMed ID: 31658965
    [Abstract] [Full Text] [Related]

  • 15. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
    Martin-Loeches I, Timsit JF, Kollef MH, Wunderink RG, Shime N, Nováček M, Kivistik Ü, Réa-Neto Á, Bruno CJ, Huntington JA, Lin G, Jensen EH, Motyl M, Yu B, Gates D, Butterton JR, Rhee EG.
    J Antimicrob Chemother; 2022 Mar 31; 77(4):1166-1177. PubMed ID: 35022730
    [Abstract] [Full Text] [Related]

  • 16. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
    Timsit JF, Huntington JA, Wunderink RG, Shime N, Kollef MH, Kivistik Ü, Nováček M, Réa-Neto Á, Martin-Loeches I, Yu B, Jensen EH, Butterton JR, Wolf DJ, Rhee EG, Bruno CJ.
    Crit Care; 2021 Aug 11; 25(1):290. PubMed ID: 34380538
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
    Bradley JS, Ang JY, Arrieta AC, Larson KB, Rizk ML, Caro L, Yang S, Yu B, Johnson MG, Rhee EG.
    Pediatr Infect Dis J; 2018 Nov 11; 37(11):1130-1136. PubMed ID: 30153232
    [Abstract] [Full Text] [Related]

  • 18. Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain.
    Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA.
    Antimicrob Agents Chemother; 2020 Dec 16; 65(1):. PubMed ID: 33077655
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
    Monogue ML, Stainton SM, Baummer-Carr A, Shepard AK, Nugent JF, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2017 Dec 16; 61(12):. PubMed ID: 28893779
    [Abstract] [Full Text] [Related]

  • 20. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Johnson MG, Bruno C, Castanheira M, Yu B, Huntington JA, Carmelitano P, Rhee EG, De Anda C, Motyl M.
    Int J Antimicrob Agents; 2021 Mar 16; 57(3):106278. PubMed ID: 33434676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.